ArticleInternational journal of surgery case reports2022
The early-stage of primary pulmonary synovial sarcoma: A case report.
Article in International journal of surgery case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary pulmonary synovial sarcoma is a rare case of lung cancer. Surgical resection is standard therapy. Early-stage and complete resection offers a good prognosis. CASE PRESENTATION: A 50-year-old woman complained of intermittent left chest pain. Chest X-ray showed a mass around the heart, MSCT also showed enhanced solid lesion in the lower left lung anterobasal segment adhered to the pericardium. The patient underwent surgery with wedge resection with both immunohistochemical (IHC) EMA and CD99 positive. After surgery, she received 3-cycle chemotherapy that consisted of a combination of doxorubicin and ifosfamide. DISCUSSION: Surgical resection is the mainstay treatment for primary pulmonary synovial sarcoma. Chemotherapy can be considered for a patient with high-risk metastases. Early-stage and young age showed a good prognosis. Patient with stage IA still survives for 49 months after completing surgical resection and chemotherapy.
conclusionResection of the tumor followed by chemotherapy may increase the survival tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.